卓然股份(688121)12月19日公告，公司及实际控制人张锦红于12月19日收到中国证监会出具的《立案告 知书》，因涉嫌信息披露违法违规等事项，根据相关法律法规，中国证监会决定对公司及实际控制人张 锦红立案。目前公司各项经营活动和业务均正常开展。立案调查期间，公司及实际控制人将积极配合中 国证监会的相关工作，并严格按照相关法律法规和监管要求及时履行信息披露义务。 同日卓然股份公告，公司12月19日收到上海证监局出具的《关于对上海卓然工程技术股份有限公司采取 责令改正措施并对张锦红、吴玉同、张笑毓采取出具警示函措施的决定》（简称《决定》）。 《决定》显示，2021年至2024年期间，卓然股份在IP0募投项目实施过程中，违规支付部分募集资金， 经由公司控股股东、董事长张锦红有效控制的供应商或资金通道方银行账户流入体外资金池进行资金调 配，部分资金在当日或次日回流至公司非募集户，其余流向了张锦红间接控制的企业。公司未如实披露 募集资金存放及实际使用情况，亦未如实披露关联方非经营性资金往来情况。 卓然股份表示，公司及相关人员在收到上述行政监管措施决定书后，高度重视决定书中所指出的问题， 将严格按照上海证监局的要求， ...

Core Viewpoint - Zhuoran Co., Ltd. and its actual controller Zhang Jinhong are facing regulatory actions from the China Securities Regulatory Commission (CSRC) due to violations related to the use of IPO fundraising, which has been ongoing for four years [2][4]. Group 1: Regulatory Actions - Zhuoran Co., Ltd. received a "Notice of Investigation" from the CSRC and an administrative regulatory decision from the Shanghai Securities Regulatory Bureau on December 19 [2][5]. - The Shanghai Securities Regulatory Bureau's investigation revealed that from 2021 to 2024, Zhuoran Co., Ltd. misused part of its IPO fundraising by transferring funds through suppliers controlled by Zhang Jinhong, leading to a diversion of funds to external pools [4]. Group 2: Violations and Consequences - The investigation confirmed that Zhuoran Co., Ltd. engaged in serious violations by transferring IPO funds to external accounts and failing to disclose the actual use of these funds, violating the "Management Measures for Information Disclosure of Listed Companies" [4]. - The Shanghai Securities Regulatory Bureau mandated Zhuoran Co., Ltd. to submit a written rectification report within 30 days and issued warning letters to responsible personnel, including Zhang Jinhong, the former chairman [4]. Group 3: Company Response - Zhuoran Co., Ltd. stated that it takes the regulatory measures seriously and will comply with the requirements set forth by the Shanghai Securities Regulatory Bureau, ensuring that it will not affect daily operations [6]. - The company confirmed that all business activities are operating normally and that it will cooperate with the CSRC during the investigation [6].

Core Viewpoint - Recently, the Shanghai Stock Exchange listed company Renfu Pharmaceutical (600079.SH) announced that it is facing administrative penalties from the Hubei Regulatory Bureau of the China Securities Regulatory Commission (CSRC) for failing to timely disclose non-operating fund occupation by its controlling shareholder, with a cumulative amount of 12.785 billion yuan from 2020 to March 2022, along with significant omissions and false records in periodic reports. The regulatory bureau intends to issue a warning and impose a total fine of 8.5 million yuan on the company [2][27]. Group 1 - Renfu Pharmaceutical failed to timely disclose non-operating fund occupation, with a cumulative amount of 12.785 billion yuan from 2020 to March 2022 [6][32]. - The company’s 2020 annual report omitted the disclosure of 2.502 billion yuan of non-operating fund occupation, which accounted for 19.26% of the net assets recorded in the report [9][35]. - In 2021, the company reported a cumulative non-operating fund occupation of 8.179 billion yuan, representing 62.97% of the net assets [8][34]. Group 2 - The company did not disclose significant related party transactions in its 2022 annual report, including a total of 1.645 billion yuan in property asset purchases from a related party, which accounted for 9.17% of the net assets [11][37]. - Renfu Pharmaceutical's 2020, 2021, and 2022 semi-annual reports contained false records, leading to inflated net profits of 143 million yuan, 72 million yuan, and 91 million yuan respectively [12][38]. Group 3 - The controlling shareholder, Wuhan Contemporary Technology Industry Group, directed Renfu Pharmaceutical to provide funds for its own needs, constituting non-operating fund occupation [18][19]. - The regulatory bureau proposed fines totaling 8.5 million yuan against Renfu Pharmaceutical and its executives for the violations, including a 3.5 million yuan fine for the company itself [19][21].

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 维权条件： 诺泰生物：根据相关司法解释，符合以下条件的投资者可发起索赔：于2022年4月28日-2024年10月24日 期间买入且有持仓，无论在2024年10月25日及之后是否卖出。（注：具体赔付范围由法院最终确定） （诺泰生物维权入口） （本文由上海市信本律师事务所合伙人赵敬国律师供稿，不代表新浪财经的观点。赵敬国律师，于1999 年取得律师资格，法学理论知识扎实，曾在高校任教。2004年起开始律师执业，承办过千余起各类诉讼 案件，积累了十分丰富的争议处理经验，尤其擅长处理证券纠纷、金融、不良资产等方面的业务。执业 至今，赵敬国律师代理投资者诉多家上市公司索赔案件，已经胜诉或已经获赔的案件包括中安科索赔、 中兵红箭索赔、步森服饰索赔、中潜股份索赔、奥瑞德索赔、獐子岛索赔、天神娱乐索赔、抚顺特钢索 赔、飞乐音响索赔、香溢融通索赔、延安必康索赔、欢瑞 ...

Core Viewpoint - The company Lifan Shuke (立方数科) is under investigation by the China Securities Regulatory Commission (CSRC) for alleged violations of information disclosure, with potential implications for investor compensation claims due to false financial reporting [2][4]. Group 1: Investigation and Allegations - On November 28, 2025, Lifan Shuke announced that it is being investigated by the CSRC for suspected violations of information disclosure laws [2][4]. - The CSRC's preliminary notice indicates that the company's annual reports for 2021, 2022, and 2023 contain false records, with the total amount of false reported revenue for 2021 and 2022 reaching 591,582,002.31 yuan, accounting for 50.91% of the total reported revenue for those two years [2][5]. - The company may face mandatory delisting due to serious violations of the Shenzhen Stock Exchange's listing rules, as it has reported false financial indicators for three consecutive years [2][5]. Group 2: Investor Compensation Opportunities - Investors who purchased Lifan Shuke shares between April 25, 2022, and April 29, 2025, and sold or continued to hold the shares after April 29, 2025, may still initiate compensation claims [3][6]. - The law firm Shanghai Jiucheng, led by attorney Xu Feng, is actively pursuing compensation claims for affected investors and has submitted multiple cases to the court for filing [3][6]. - The law firm has a history of successfully representing investors in similar cases, with no fees charged to investors unless compensation is awarded [6].

Core Viewpoint - The article discusses the ongoing legal actions against Dinglong Culture (002502) for false disclosures, highlighting the potential for investor compensation due to the company's financial misreporting [1][2][3][4] Group 1: Legal Proceedings - The law firm Shanghai Jiucheng has submitted multiple claims to the Shantou Intermediate People's Court regarding investor compensation related to Dinglong Culture's false statements, with some cases already formally accepted by the court [1][2] - The legal team continues to accept new claims from investors who believe they are entitled to compensation [1][2] Group 2: Regulatory Findings - On September 11, 2024, Dinglong Culture received an administrative penalty from the Guangdong Regulatory Bureau of the CSRC, confirming violations in information disclosure [3] - The company was found to have inflated titanium concentrate production by 23,120.55 tons in 2021, with sales contracts executed without actual production or delivery, violating accounting standards [3] Group 3: Financial Misreporting - Dinglong Culture included inflated inventory and profits in its consolidated financial statements, leading to false disclosures in its 2021 annual report and 2022 semi-annual report [2][3] - In 2021, the company inflated inventory by 9,580,821.56 yuan and total profit by 2,147,160.01 yuan, which constituted 16.30% of the reported profit for that period [2][3] - For the first half of 2022, the inflated operating revenue was 45,778,689.00 yuan and inflated profit was 37,903,539.96 yuan, representing 19.72% and 64.10% of the reported figures, respectively [2][3] Group 4: Investor Compensation Opportunities - Investors who purchased Dinglong Culture stock between April 30, 2022, and April 29, 2023, and sold or held the stock after April 29, 2023, may still have opportunities for compensation [4]

Core Viewpoint - Guangdong Huilun Crystal Technology Co., Ltd. is facing administrative penalties from the China Securities Regulatory Commission (CSRC) for violations related to information disclosure and financial misreporting [1][3][6] Group 1: Information Disclosure Violations - Huilun Crystal failed to disclose related party fund occupation in its 2020 annual report, with a total fund occupation amounting to 28,330,000 yuan, which represented 5.12% of the company's disclosed net assets for that year [7][8] - By March 2025, the related parties had returned the occupied funds and interest, but the failure to disclose this in the 2020 report constitutes a significant omission [7] Group 2: Financial Misreporting - The company inflated costs and revenues in its 2021 and 2022 annual reports to cover up the fund occupation, resulting in a reported increase in costs of 8,639,070.52 yuan for 2021 and 23,954,692.38 yuan for 2022 [8] - Huilun Crystal also reported inflated revenues of 25,489,938.60 yuan in 2021 and 62,333,644.39 yuan in 2022, which accounted for 3.89% and 15.79% of the reported revenues for those years, respectively [8] Group 3: Regulatory Actions - The CSRC's Guangdong Regulatory Bureau plans to impose corrective measures, warnings, and fines on Huilun Crystal's actual controller Zhao Jiqing and other responsible personnel [9] - Investors affected by the company's actions are encouraged to register for compensation claims through legal representation, with specific conditions outlined for eligibility [10][11]

Core Viewpoint - Shanghai Broadband Technology Co., Ltd. (ST Huke, stock code: 600608) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may lead to civil compensation claims from affected investors [1][4]. Group 1: Company Investigation - The CSRC has decided to investigate ST Huke due to alleged violations of information disclosure regulations as per the Securities Law of the People's Republic of China [1][4]. - The investigation could result in civil liability for the company, its controlling shareholders, and executives if investors suffer losses due to false statements [1][4]. Group 2: Investor Compensation - A lawyer from Shanghai Hanlian Law Firm is collecting claims from investors who purchased ST Huke securities before December 13, 2025, and either sold or held them after that date [2][5]. - The conditions for compensation claims will be adjusted based on the conclusions of the CSRC's administrative penalties and the final court rulings regarding the legal time points, compensation objects, and standards [2][5]. Group 3: Legal Process and Requirements - The progress of civil compensation lawsuits may be affected by whether the company is delisted or enters bankruptcy proceedings [6]. - Investors wishing to register for compensation must provide specific documents, including a copy of their ID, a securities account confirmation, and transaction records [6].

Core Viewpoint - Lingnan Ecological Cultural Tourism Co., Ltd. has been convicted of bid-rigging, resulting in a fine of 600,000 RMB and prison sentences for two employees [1][10]. Group 1: Legal Issues - The company was found guilty of bid-rigging, with a fine of 600,000 RMB imposed by the Henan Province Tangyin County People's Court [4][5]. - Two employees from the company's subsidiary were sentenced to ten months in prison, with one receiving a fine of 30,000 RMB and the other 25,000 RMB [4][5]. - The case originated from a bidding process for a project worth 96.2265 million RMB, where the employees failed to comply with legal bidding procedures [4][16]. Group 2: Company Response and Compliance - The company believes that this legal issue does not trigger mandatory delisting under the Shenzhen Stock Exchange rules [2][11]. - Lingnan plans to enhance compliance training for its board members and management to prevent future legal issues [2][11]. Group 3: Financial Performance - For the first three quarters of the year, the company reported total revenue of 253 million RMB, a significant decrease of 68.75% year-on-year [9][22]. - The net profit attributable to shareholders was a loss of 206.23 million RMB, reflecting a 23.34% increase in losses compared to the previous year [9][22]. - The company's total assets decreased by 5.16% to approximately 13.62 billion RMB, while equity attributable to shareholders fell by 19.37% [22].

Core Viewpoint - ST Lingnan has been sentenced to a fine of 600,000 yuan for collusion in bidding, with two responsible personnel receiving suspended prison sentences, but the company claims this has not significantly impacted its operations [1][2]. Legal Issues - The case originated from a project won by ST Lingnan in June 2021, with a contract value of 96.2265 million yuan, representing 9.04% of the company's latest audited net assets [2]. - The court found that employees of ST Lingnan's subsidiary failed to comply with legal bidding procedures, leading to the charges of collusion [2]. - The company has stated that the judgment is not yet effective and has not had a major impact on its operations, nor does it trigger mandatory delisting conditions [2]. Financial Challenges - ST Lingnan is facing multiple challenges, including overdue debts, litigation disputes, and continuous losses [3]. - As of November 15, the company reported overdue interest debts of 139 million yuan, which is 13.08% of its audited net assets for 2024 [3]. - The company has also disclosed that it has faced new litigation and arbitration cases totaling approximately 113 million yuan, which is 10.60% of its latest audited net assets [3]. Performance Issues - ST Lingnan has reported consecutive losses over the years, with a cumulative net profit loss of 3.63 billion yuan from 2022 to 2024 [4]. - As of the third quarter of 2025, the net profit loss was 206 million yuan, primarily due to difficulties in collecting receivables, exacerbated by tight local government finances [4]. - The company’s accounts receivable balance reached 2.259 billion yuan by the end of 2024, indicating reliance on local government payments for revenue [4]. Compliance Risks - ST Lingnan is also facing other compliance risks, including an investigation by the China Securities Regulatory Commission for information disclosure violations [5]. - The company has initiated legal action against its former controlling shareholder for the recovery of 142 million yuan in misappropriated funds [5].